April 24, 2017 07:00 ET
Amedica Announces Regulatory Clearance to Market and Sell Valeo® Silicon Nitride Spinal Implants in Australia
Australian Marketing Clearance Provides Opportunities for Global Expansion
SALT LAKE CITY, UT--(Marketwired - Apr 24, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative medical device company that develops and commercializes silicon nitride, is pleased to announce it has been granted marketing clearance for its Valeo interbody fusion devices in Australia.
The Valeo product line is made entirely of Amedica's proprietary medical grade silicon nitride ceramic -- an ideal material for fusion because of its nanostructured surface, osteoconductivity, osteoinductivity, anti-microbial properties, and ease of radiographic imaging.
"The Australian clearance is a tremendous opportunity for Amedica. Interestingly, during 1986-1988, Australian surgeons and engineers were the first to synthesize reaction-bonded silicon nitride, and implant the material in lumbar spine fusion patients. Favorable outcomes in terms of pain relief and successful fusion were reported at the 15-year follow-up time interval. Thus, the pioneering clinical use of silicon nitride in spine fusion originated in Australia, and we are excited to see the material return to its place of birth," said Dr. Sonny Bal, CEO. "The successful outcomes from Australia are now validated by 45 scientific papers published by Amedica in top-tier peer journals, and clinical data that will be published throughout this year. We look forward to working with Australian surgeons, and providing them with improved options for spinal fusion surgery."
